Trials in Idaho.
7 APOE4-relevant Alzheimer’s trials run in Idaho — 1 of them recruiting. Each one translated into plain English, with our read on what it means for an APOE4 carrier.
- Built exclusively for APOE 4/4 carriersNCT02565511A Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease
This trial tested two investigational drugs, CAD106 (a vaccine-like immunotherapy targeting amyloid) and CNP520 (a small molecule targeting amyloid…
- Built specifically for APOE4 carriersNCT03131453A Study of CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease
This trial tested CNP520, a drug designed to reduce amyloid buildup in the brain, against a placebo in cognitively normal older adults at elevated risk for…
- High ARIA risk for carriersNCT04437511A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)
This Phase 3 trial tested donanemab, an anti-amyloid antibody drug, against placebo in people with early Alzheimer's disease. Researchers measured how well it…
- Drug trial, genotype not specified, ARIA riskNCT05026866A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)
This trial tests donanemab, an anti-amyloid antibody given by infusion, against a placebo in people with no memory or thinking problems but signs of amyloid in…
- Drug trial, APOE4 handling not statedNCT06653153A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3)
This trial tests remternetug, an anti-amyloid antibody drug, against a placebo. It measures how long it takes for memory, thinking, or daily-function problems…
- Open to patients, genotype not requiredNCT06881836A Study of ONO-2020 in Participants With Mild to Moderate Alzheimer's Disease
This trial tests ONO-2020, an experimental pill that works on gene regulation, in people already diagnosed with mild to moderate Alzheimer's. Researchers want…
- Prior participants only, not APOE4-specificNCT07602582A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT).
This Phase 3 trial tests whether people who already took donanemab in an earlier study (TRAILBLAZER-ALZ 3) get clinical benefit from yearly doses compared with…
Copy a forum-ready post
Keep exploring
Educational, not medical advice. Trial decisions belong between you and your physician.